Paper Details

  1. Home
  2. Paper Details

Comparison of the Hepatotoxic Potential of Two Treatments for Autosomal-Dominant Polycystic Kidney DiseaseUsing Quantitative Systems Toxicology Modeling.

Author: HowellB A, PellegriniL, ShodaL K M, WoodheadJ L

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Tolvaptan, a vasopressin V<sub>2</sub> receptor antagonist, is approved for treating ADPKD but can cause drug-induced liver injury.
Paper Details　
Original Abstract of the Article :
Label="PURPOSE" NlmCategory="OBJECTIVE">Autosomal-dominant polycystic kidney disease (ADPKD) is an orphan disease with few current treatment options. The vasopressin V<sub>2</sub> receptor antagonist tolvaptan is approved in multiple countries for the treatment of ADPKD, however its use is associate...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6944674/

データ提供：米国国立医学図書館（NLM）

Tolvaptan: A Double-Edged Sword for Autosomal-Dominant Polycystic Kidney Disease (ADPKD)?

This study delves into the complex world of autosomal-dominant polycystic kidney disease (ADPKD), a condition that can be as challenging to understand as a labyrinthine desert. The researchers explored the potential hepatotoxic effects of tolvaptan, a medication currently used to treat ADPKD. The study utilized quantitative systems toxicology modeling to compare the liver-damaging potential of tolvaptan with other treatment options. The results point to a potential for liver injury with tolvaptan, highlighting the need for careful monitoring and management of patients.

Tolvaptan: Navigating the Risks

Tolvaptan has shown promise in slowing the progression of ADPKD, but this study underscores the importance of understanding its potential risks. The researchers found that tolvaptan is associated with a higher risk of drug-induced liver injury compared to other treatment options for ADPKD. This finding emphasizes the need for close monitoring of liver function in patients taking tolvaptan.

Living With ADPKD: A Balancing Act

Living with ADPKD can be like navigating a challenging desert landscape. While there are treatments available, it's important to be aware of the potential risks associated with each one. Tolvaptan may be an effective treatment option for some patients, but it is crucial to have regular checkups and carefully monitor liver function to minimize the risk of complications.

Dr.Camel's Conclusion

This study provides valuable insights into the potential hepatotoxic effects of tolvaptan, a medication used to treat ADPKD. The use of quantitative systems toxicology modeling highlights the importance of careful consideration of treatment risks and benefits. The study emphasizes the need for close monitoring of liver function in patients taking tolvaptan and for ongoing research to develop safer and more effective treatment options for ADPKD.

Date :
  1. Date Completed 2020-06-01
  2. Date Revised 2020-06-01
Further Info :

Pubmed ID

31909447

DOI: Digital Object Identifier

PMC6944674

Related Literature

Article Analysis
・Side Effects of tolvaptan (kidney disease)
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.